Example: Heart Attack

Search clinical trials for: Etoposide

Total 1468 results

NCT04490421

Not yet recruiting

Carillizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Conditions: Lung Neoplasm
NCT04490590

Recruiting

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Conditions: NK/T-Cell Lymphoma
NCT04487756

Not yet recruiting

Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Conditions: Extensive-stage Small Cell Lung Cancer
NCT04486391

Not yet recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT04484506

Recruiting

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

Conditions: NK/T Cell Lymphoma Nos
NCT04472949

Not yet recruiting

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Conditions: Small Cell Lung Cancer; Lung Cancer
NCT04469530

Not yet recruiting

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Conditions: Solid Tumor
NCT04452370

Not yet recruiting

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Conditions: Triple Negative Breast Cancer
NCT04449861

Not yet recruiting

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Conditions: Small Cell Lung Carcinoma Extensive Disease
NCT04432714

Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Conditions: DLBCL; Untreated; MYC Gene Rearrangement
NCT04425070

Not yet recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Conditions: Peripheral T-cell Lymphoma; NK/T-cell Lymphoma
NCT04422210

Recruiting

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Conditions: Small Cell Lung Cancer
NCT04405375

Recruiting

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type
NCT04397003

Not yet recruiting

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer

Conditions: Extensive-stage Small Cell Lung Cancer
NCT04388839

Not yet recruiting

Evolutionary Therapy for Rhabdomyosarcoma

Conditions: Rhabdomyosarcoma
NCT04383977

Not yet recruiting

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Conditions: Ovarian Cancer
NCT04380636

Recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
NCT04378647

Not yet recruiting

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Conditions: Hodgkin Lymphoma, Adult
NCT04372927

Not yet recruiting

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
NCT04363255

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Conditions: Small Cell Lung Carcinoma
NCT04364048

Recruiting

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Conditions: Lung Cancer; Non-small Cell Carcinoma
NCT04356690

Recruiting

Etoposide in Patients With COVID-19 Infection

Conditions: COVID-19
NCT04346914

Recruiting

Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Conditions: Extensive Stage Small Cell Lung Cancer
NCT04326439

Recruiting

AflacLL1901 (CHOA-AML)

Conditions: Acute Myeloid Leukemia; AML, Childhood
NCT04325425

Not yet recruiting

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Conditions: Neuroendocrine Carcinoma
NCT04322318

Not yet recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Conditions: Anaplastic Kidney Wilms Tumor; Recurrent Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor
NCT04308785

Not yet recruiting

Atezolizumab Consolidation in Limited Stage Small Cell Lung Cancer

Conditions: Carcinoma, Small Cell Lung
NCT04301843

Not yet recruiting

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Conditions: Neuroblastoma
NCT04301076

Not yet recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Conditions: Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection
NCT04293562

Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Conditions: Acute Myeloid Leukemia
NCT04268121

Not yet recruiting

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Conditions: Neuroendocrine Carcinoma; Digestive Cancer
NCT04254471

Recruiting

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Conditions: Extensive-stage Small Cell Lung Cancer
NCT04256421

Recruiting

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Conditions: Small Cell Lung Cancer
NCT04234607

Not yet recruiting

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Conditions: Extensive Small Cell Lung Cancer
NCT04231877

Not yet recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Conditions: Aggressive Non-Hodgkin Lymphoma; ALK-Positive Large B-Cell Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
NCT04221035

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Conditions: High-Risk Neuroblastoma
NCT04221529

Recruiting

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Conditions: SCLC, Extensive Stage
NCT04217798

Not yet recruiting

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Conditions: Ovarian Cancer
NCT04211987

Recruiting

Fast Track Total Hip Arthroplasty vs Standard Care

Conditions: Hip Osteoarthritis; Hip Pain Chronic
NCT04203511

Withdrawn

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Conditions: Non-small Cell Lung Cancer
NCT04189094

Not yet recruiting

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Conditions: Small Cell Lung Cancer Limited Stage
NCT04189952

Not yet recruiting

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Conditions: Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia; Marginal Zone Lymphoma
NCT04182698

Recruiting

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Conditions: Patients With Non-small Cell Lung Cancer
NCT04177004

Not yet recruiting

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
NCT04154189

Recruiting

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Conditions: Osteosarcoma
NCT04152577

Recruiting

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

Conditions: Lymphoma, B-Cell
NCT04139304

Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Conditions: Ann Arbor Stage I Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Plasmablastic Lymphoma
NCT04134247

Not yet recruiting

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Conditions: Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT04129710

Recruiting

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Conditions: Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
NCT04116359

Not yet recruiting

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Conditions: Metastatic NUT Carcinoma; Unresectable NUT Carcinoma